e-learning
resources
Copenhagen 2005
Sunday 18.09.2005
Cardiovascular disease and obstructive sleep apnoea: risks and remedy
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Can we correct the cardiovascular risks with treatment?
J. Stradling (Oxford, United Kingdom)
Source:
Annual Congress 2005 - Cardiovascular disease and obstructive sleep apnoea: risks and remedy
Session:
Cardiovascular disease and obstructive sleep apnoea: risks and remedy
Session type:
Symposium
Number:
120
Disease area:
Sleep and breathing disorders
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Stradling (Oxford, United Kingdom). Can we correct the cardiovascular risks with treatment?. Annual Congress 2005 - Cardiovascular disease and obstructive sleep apnoea: risks and remedy
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on acute decompensated pulmonary hypertension
Clinical case discussion: ERS guidelines on high flow nasal cannula in acute respiratory failure: from the clinical cases to the scientific evidence
Adherence predictors to positive airway pressure (PAP) treatment in patients with obstructive sleep apnea (OSA)
Related content which might interest you:
Continuous positive airway pressure (CPAP) supported by telemedicine improves sleepiness and quality of life but not blood pressure in high cardiovascular risk obstructive sleep apnea (OSA): A randomized, controlled trial
Source: Annual Congress 2013 –Ask, see and do: old and new technology in sleep disordered breathing
Year: 2013
Sleep apnoea and systemic hypertension
Source: Eur Respir Mon 2010; 50: 150-173
Year: 2010
Can psychological factors help us to determine adherence to CPAP? A prospective study
Source: Eur Respir J 2004; 24: 461-465
Year: 2004
CPAP treatment reduce blood pressure in patients with recent diagnosis of systemic hypertension and obstructive sleep apnoea -hypopnoea (OSAH). A controlled study
Source: Annual Congress 2008 - Clinical aspects of continuous positive airway pressure therapy
Year: 2008
Increased incidence of nonfatal cardiovascular events in stroke patients with sleep apnoea: effect of CPAP treatment
Source: Eur Respir J 2012; 39: 906-912
Year: 2012
Nasal continuous positive airway pressure in stroke patients with sleep apnoea: a randomized treatment study
Source: Eur Respir J 2001; 18: 630-634
Year: 2001
Resting electrocardiographic (EKG) changes, the cardiovascular risk factors and the effect of CPAP (continuous positive airways pressure) therapy on high blood pressure evolution in patients with sleep apnoea syndrome
Source: Eur Respir J 2005; 26: Suppl. 49, 564s
Year: 2005
Should obstructive sleep apnoea be treated regarding the related cardiovascular risk in non sleepy patients?
Source: Annual Congress 2006 - Obstructive sleep apnoea and cardiovascular diseases
Year: 2006
The influence of 3-weeks‘ therapy of continous positive airway pressure (CPAP) on serum leptin and homocysteine concentration in patients with obstructive sleep apnea (OSA)
Source: Annual Congress 2005 - Metabolic control in OSA
Year: 2005
Improvement of machine compliance when switching patients with OSA to C-flex
Source: Annual Congress 2005 - What should we know about our SAS patients
Year: 2005
Treatment options for central sleep apnea (including auto-CPAP)
Source: Annual Congress 2005 - Central sleep apnoea
Year: 2005
Controlled, prospective trial of psychosocial function before and after continuous positive airway pressure therapy
Source: Eur Respir J 2001; 18: 996-1002
Year: 2001
CPAP: evidence-based data regarding compliance, efficacy and side-effects
Source: Annual Congress 2005 - PG12 - Sleep-related problems: treatment of obstructive sleep apnoea - current concepts and perspectives
Year: 2005
Early treatment of obstructive apnoea and stroke outcome: a randomised controlled trial
Source: Eur Respir J 2011; 37: 1128-1136
Year: 2011
Positive effect of CPAP treatment on the control of difficult-to-treat hypertension
Source: Eur Respir J 2007; 29: 951-957
Year: 2007
Compliance with continuous positive airway pressure in patients with sleep apnea/hypopnea syndrome
Source: Annual Congress 2007 - Sleep apnoea
Year: 2007
Continuous positive airway pressure treatment for sleep apnoea: compliance increases with time in continuing users
Source: Eur Respir J 2006; 27: 761-766
Year: 2006
Treatment with CPAP reduces mortality in patients with obstructive sleep apnoea syndrome within less than 3 years
Source: Annual Congress 2006 - Therapeutic effects in obstructive sleep apnoea
Year: 2006
Effect of continuous positive airway pressure treatment on hypoadiponectinemia in male patients with obstructive sleep apnea syndrome
Source: Annual Congress 2005 - Metabolic control in OSA
Year: 2005
Pharmacological management of sleep-disordered breathing
Source: Eur Respir Mon 2010; 50: 321-339
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept